Status:
COMPLETED
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
Lead Sponsor:
University of Utah
Conditions:
SARS CoV-2 Infection
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e....
Eligibility Criteria
Inclusion
- 1\. Age ≥18
- 2\. Hospitalized and symptomatic (cough, fevers, SOB, or sputum production)
- 3\. SARS CoV-2 laboratory positive obtained within 14 days of enrollment
Exclusion
- 1\. None
Key Trial Info
Start Date :
March 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 9 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04319731
Start Date
March 20 2020
End Date
June 9 2020
Last Update
April 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah Health
Salt Lake City, Utah, United States, 84132